Next-generation spray dried plasma demonstrates safety profile comparable to standard frozen plasma, advancing the future of decentralized transfusion medicine

BOSTON, June 18, 2026 /PRNewswire/ — Velico today announced the publication of its Phase 1 first-in-human clinical trial evaluating Frontline On Demand Plasma (ODP), a next-generation spray-dried plasma product designed to transform access to lifesaving plasma transfusion in emergency, military, prehospital and austere care environments.

The multicenter, randomized, dose-escalation study, published in the journal Transfusion, demonstrated that Velico’s spray-dried plasma was well tolerated across all dose levels and exhibited a safety profile comparable to standard frozen plasma (PF24).

The publication, titled “Next generation spray-dried on-demand plasma: A multicenter, randomized, dose-escalation, first-in-human safety study,” marks a major milestone in the evolution of decentralized plasma capabilities.

“This study represents a defining moment not only for Velico, but for the future of trauma care and transfusion medicine,” said Richard Meehan. “For decades, the logistical limitations of plasma have prevented widespread access in frontline and resource-constrained settings. FrontlineODP™ has the potential to fundamentally change that paradigm by enabling rapid, portable and operationally resilient plasma availability wherever patients need it most.”

Advancing the Future of Plasma Access

Plasma transfusion has been shown to improve survival outcomes in patients at risk of hemorrhagic shock, particularly when administered early. However, traditional frozen plasma products require cold-chain storage, thawing infrastructure and complex logistics – barriers that significantly limit availability in remote, prehospital, military and disaster-response settings.

Velico’s FrontlineODP™ addresses these challenges through proprietary spray-drying technology that enables:

Rapid reconstitution
Durable ultra lightweight PVC packaging
Elimination of frozen cold-chain dependency
Increased operational portability
Expanded deployment in austere and emergency environments
Decentralized production

The Phase 1 study enrolled 24 healthy volunteers across three sequential dose-escalation cohorts. Participants received escalating doses of FrontlineODP™ up to 800mL, including a randomized, double-blind crossover comparison against standard frozen plasma.

Key findings from the study include:

All 24 participants successfully completed the trial
Infusions were well tolerated across all cohorts
No thromboembolic events were observed
Treatment-emergent adverse events occurred at similar frequencies between FrontlineODP and frozen plasma
Minor coagulation changes observed were not clinically significant
Protein preservation within the FrontlineODP™ spray dried plasma manufacturing system was successfully demonstrated

“These results validate the promise of spray-dried plasma as a next-generation transfusion platform,” said Jose A. Cancelas. “The ability to safely deliver plasma without traditional cold-chain constraints has profound implications for trauma systems, military medicine and emergency preparedness globally.”

Supporting Military and Civilian Readiness

Velico’s decentralized plasma technology is being actively evaluated for applications across military medicine, disaster response, civilian trauma systems and national resilience programs worldwide.

The company’s FrontlineODP™ and veliPod™ decentralized production platforms are designed to support sovereign blood resilience strategies by enabling localized plasma manufacturing and rapid deployment capabilities.

“With growing global demand for resilient medical infrastructure, these findings reinforce the importance of deployable, decentralized blood solutions,” added Meehan. “Velico remains committed to advancing technologies that improve survivability and operational readiness in the world’s most challenging environments.”

The full study is available online in Transfusion:
https://doi.org/10.1111/trf.70262

CAUTION:
The FrontlineODP™ Spray Dried Plasma System has not received FDA or EU approval for any indication. Regulatory requirements of individual countries and regions will determine approval, clearance, or market availability.

This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50121C00059

About Velico

Velico is a private US medical technology company, committed to the mission of eliminating preventable death from bleeding. Headquartered in Beverly, Massachusetts, USA. Velico personnel have substantial expertise and experience in transfusion medicine and medical device development. In support of its mission, Velico is developing partnerships with civilian, government and military blood center leadership, trauma surgeons, emergency medical physicians, military medics and first responders worldwide.

For more information visit www.veli.co